Novartis Stock Forecast, Price & News

Novartis' stock was trading at $82.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVS shares have increased by 4.3% and is now trading at $85.69.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novartis.

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Novartis.

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Tuesday, July, 21st. The company reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.31 by $0.05. The business earned $11.35 billion during the quarter, compared to the consensus estimate of $11.77 billion. Novartis had a return on equity of 24.14% and a net margin of 14.96%. The business's revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.34 EPS.
View Novartis' earnings history.

Novartis declared an annual dividend on Monday, February 3rd. Stockholders of record on Wednesday, March 4th will be given a dividend of $3.0425 per share on Thursday, March 12th. This represents a yield of 2%. The ex-dividend date of this dividend is Tuesday, March 3rd. This is a positive change from Novartis's previous annual dividend of $2.86.
View Novartis' dividend history.

10 Wall Street analysts have issued 12 month price objectives for Novartis' stock. Their forecasts range from $100.00 to $116.00. On average, they expect Novartis' stock price to reach $108.00 in the next year. This suggests a possible upside of 26.0% from the stock's current price.
View analysts' price targets for Novartis.

Novartis saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 2,470,000 shares, an increase of 14.9% from the August 31st total of 2,150,000 shares. Based on an average trading volume of 1,680,000 shares, the short-interest ratio is presently 1.5 days. Currently, 0.1% of the shares of the stock are sold short.
View Novartis' Short Interest.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Merck & Co., Inc. (MRK), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), AstraZeneca (AZN), Sanofi (SNY), Commonwealth Bank of Australia (CSLLY), GlaxoSmithKline (GSK) and Celgene (CELG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), The Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Scharf Investments LLC (0.05%), Envestnet Asset Management Inc. (0.04%), Douglas Lane & Associates LLC (0.03%), Gofen & Glossberg LLC IL (0.01%), Confluence Investment Management LLC (0.01%) and Bartlett & Co. LLC (0.01%).

NVS stock was sold by a variety of institutional investors in the last quarter, including Scharf Investments LLC, Verity & Verity LLC, Envestnet Asset Management Inc., CWM LLC, Park National Corp OH, FNY Investment Advisers LLC, Regentatlantic Capital LLC, and Minot Wealth Management LLC.

NVS stock was acquired by a variety of institutional investors in the last quarter, including Douglas Lane & Associates LLC, Cardinal Capital Management Inc., Martin Investment Management LLC, Pacer Advisors Inc., Hall Laurie J Trustee, Professional Advisory Services Inc., Crossmark Global Holdings Inc., and Trust Co. of Oklahoma.

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVS stock can currently be purchased for approximately $85.69.

Novartis has a market capitalization of $196.12 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 103,914 workers across the globe.

The official website for Novartis is www.novartis.com.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]